Rethinking the Colonoscopy: The 13-Year NordICC Trial Verdict
It is one of the most dreaded, invasive, and universally recommended cancer screening procedures. But does it actually save lives? A landmark paper published in The Lancet challenges the assumed mortality benefits of population-wide colonoscopy screening.
1. The Invasive Standard of Care
For decades, the colonoscopy has been heralded as the gold standard for colorectal cancer (CRC) screening. The logic is mechanistically sound: insert a camera into the colon, find pre-cancerous polyps, and remove them before they can metastasize. However, the procedure requires a highly unpleasant bowel preparation regimen, sedation, and time off work. Despite its widespread implementation, particularly in the United States, colonoscopy screening was originally introduced without high-quality evidence from randomized controlled trials.
To fill this critical evidence gap, the Northern-European Initiative on Colorectal Cancer (NordICC) trial was initiated. This multicountry, population-based randomized controlled trial included 84,583 men and women aged 55-64 years from Norway, Poland, and Sweden. Participants were randomly allocated in a 1:2 ratio to either receive an invitation to undergo a single screening colonoscopy or to receive no screening. Now, with 13 years of follow-up data published in The Lancet by Kaminski et al. (2026), the results force us to confront uncomfortable questions about the true utility of this heavy-handed intervention.
2. The 13-Year Data: Incidence Down, Mortality Unchanged
The primary outcomes of the NordICC trial evaluated after 13 years were CRC incidence and mortality, analyzed strictly on an intention-to-screen basis (which reflects real-world public health outcomes).
Did the screening prevent cancer? Yes. The 13-year risk of developing CRC was 1.46% (375 of 28,217) in the screening invitation group, compared to 1.80% (912 of 56,366) in the no-screening group. This translates to a risk ratio (RR) of 0.81 (95% CI 0.71–0.90), meaning being invited to a colonoscopy reduced the incidence of colorectal cancer by roughly 19%.
However, the crucial metric is whether the procedure prevented death. Here, the data fell short. The 13-year CRC mortality was 0.41% (106 deaths) in the screening group versus 0.47% (236 deaths) in the no-screening group. This yielded an intention-to-screen RR of 0.88 (95% CI 0.68–1.08), which is not statistically significant. After more than a decade of tracking, inviting a population to undergo a colonoscopy did not significantly reduce their risk of dying from colorectal cancer.
3. The Participation Problem and the "Per-Protocol" Reality
A major caveat of the NordICC trial is the human element: nobody likes getting a colonoscopy. Overall, only 42.0% (11,841 of 28,217) of the participants invited to the screening actually underwent the procedure.
When the researchers conducted a "per-protocol" analysis—estimating the effect if 100% of the invited individuals had actually been screened—the numbers improved. In the per-protocol analysis, CRC incidence dropped to 1.00% (RR 0.55; 95% CI 0.33–0.81), representing a 45% relative risk reduction. Yet, even among those who actually got the procedure, the per-protocol effect on CRC mortality remained highly imprecise (RR 0.70; 95% CI 0.26–1.25).
4. The Paradox of Modern Medicine
Why did a procedure that physically removes precancerous lesions fail to significantly reduce mortality? The answer lies in the miraculous advancement of modern oncology. When the NordICC trial was designed almost 20 years ago, the expected CRC mortality in the no-screening group was projected to be 0.82%. Instead, the observed mortality was only 0.47%—nearly half of what was expected without any screening intervention.
As the authors note, the prognosis of colorectal cancer has improved dramatically over the past two decades due to profound advances in chemotherapy, surgery, radiotherapy, and immunotherapy. Colorectal cancer has evolved from a disease with a highly fatal trajectory into a chronic disease that most individuals survive, regardless of whether it was caught via screening or through later clinical symptoms. If the baseline risk of dying from the disease is already exceptionally low thanks to modern treatments, a screening test simply cannot demonstrate a massive mortality benefit.
💡 My Practical Perspective: Is the Burden Justified?
For many individuals, the prospect of a colonoscopy is a source of intense anxiety. The fasting, the harsh laxative preparations, the necessity of sedation, and the loss of personal dignity and time constitute a massive physiological and psychological burden. We willingly endure this burden under the promise that it is a life-saving necessity.
However, the 13-year NordICC data forces us to step back and weigh this heavy intervention rationally. If a single colonoscopy reduces the absolute risk of getting colorectal cancer by a mere 0.34 percentage points and fails to significantly reduce the risk of dying from it, we must ask: Is population-wide, mandatory colonoscopy screening the most scientifically elegant approach?
As the Lancet authors bravely concluded, "On the population level, screening benefits must be weighed against other expenditures that promote public health". With the rise of highly accurate, non-invasive alternatives like Fecal Immunochemical Testing (FIT) and emerging blood-based ctDNA liquid biopsies, the era of relying solely on the invasive colonoscopy as the primary frontline screening tool may be coming to a well-deserved end.